DMG Deutsche Malaria GmbH

DMG Deutsche Malaria GmbH is a Hamburg, Germany based privately-held company and has collaborations with partners from academia and business. Our shareholders are motivated supporters who bring a wealth of experience and expertise from medical and scientific research and development, commerce, finance and law.

We have collaborations with renowned institutions and companies in Germany and the UK, in the fields of tropical diseases, molecular biology, bioinformatics, immunology, toxicology, drug formulation and preclinical and clinical trials.

DMG Deutsche Malaria GmbH has been or is supported by Medicines for Malaria Venture (MMV) – a not for profit organisation funded by the Bill And Melinda Gates Foundation, European and Developing Countries Clinical Trials Programme (EDCTP), World Health Organisation (WHO) and the EU Malaria Fund (EUMF).

On June 1, 2021, DMG Deutsche Malaria GmbH concluded a contract with the EU Malaria Fund (EUMF) to receive €2.7 million for the development of DMG’s antimalarial triple combination therapy.

Further partners are wellcome to join our efforts to speed up the next steps of the drug development  program with the goal to bring highly relevant therapeutic options to the market.